Evidence map›Paper›PMID 42816592›Full record

ReviewEuropean journal of human genetics : EJHG2026

Expanded carrier screening in China: a focused narrative review and conceptual implementation framework.

Liling Liu, Honglian Wu, Ming Zhang, Yinghui Ye, Dong Yu, Ming Qi, Xutao Hong

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liling LiuDepartment of Reproductive Medicine and Genetics Center, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Honglian WuDepartment of Reproductive Medicine Center, Lishui People's Hospital, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui, China.
Ming ZhangReproductive Medical Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yinghui YeDepartment of Reproductive Endocrinology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Dong YuCenter for Human Genome Research, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Ming QiZhejiang California Nano-system Institute, Shaoxing Branch, Shaoxing, China. mingqi@zju.edu.cn.ORCID http://orcid.org/0000-0002-8421-6727
Xutao HongZhejiang California Nano-system Institute, Shaoxing Branch, Shaoxing, China. hongxt@zju.edu.cn.ORCID http://orcid.org/0000-0002-9971-8332

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expanded carrier screening (ECS) is increasingly used in China, but implementation remains heterogeneous across regions, laboratories, and reproductive-care settings. This focused narrative review synthesizes Chinese evidence on population variation, panel design, analytical methods, variant interpretation, couple-level reproductive risk, and health-system delivery. The review was informed by a reproducible PubMed search through 29 July 2026, supplemented by targeted identification of Chinese empirical studies and professional guidance. Chinese studies demonstrate substantial variation in carrier frequencies and screening yield across populations, while reported carrier and at-risk couple (ARC) rates are strongly influenced by panel composition, analytical methods, and variant-reporting criteria, particularly the inclusion of low-penetrance variants. Technical limitations at structurally complex loci and uneven access to genetic counseling and laboratory resources further affect implementation. On this basis, we propose a review-derived conceptual framework centered on universal minimum access, core screening principles, population-informed content adaptation, separation of variant-level classification from couple-level reproductive-risk assessment, and health-system support. Regional epidemiology and founder variants may inform panel content but should not determine screening eligibility. The framework also emphasizes partner testing, counseling and referral pathways, quality assurance, reimbursement, and measurable implementation outcomes. It is intended to organize current evidence and support future consensus development rather than function as a validated clinical guideline. Prospective multicenter evaluation, stakeholder consensus, and China-specific health-economic analyses are needed before national practice recommendations can be established.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.